MICB and Miyoshi myopathy: Besides its direct impact on NK cells, MLN4924, along with a DCN1 inhibitor (NAcM-OPT), has been shown to enhance the cell surface presentation of the NKG2D ligands MICA and MICB on both MM cell lines and patient-derived MM cells.